Organogenesis Holdings Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Organogenesis Holdings Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	139	199	193	261	338	467	451	433	482	564
Cost of revenue	48.2	61.2	68.8	75.9	87.3	114	105	106	116
Gross profit	90.5	137	125	185	251	353	346	327	366
Research and development	6.28	9.07	10.7	14.8	20.1	30.7	39.8	44.4	50.3	44.5
Selling, general and administrative	93	134	162	200	204	250	284	270	295	326
Operating expenses	99.3	143	176	215	224	281	324	421	483	519
Operating income	-8.78	-5.49	-51.6	-29.9	26.7	72.2	22.3	12.5	-1.28	44.7
Interest expense	5.63	8.01	10.8	9	11.3	7.24	2.01	2.19	1.54	-2.28
Interest income	0.15	0.13	0.06
Other non-operating income	-5.93	-9.06	-13.2	-8.71	-8.94	-9.13	-2.02	-2.13	-1.52	2.28
Pre-tax income	-14.7	-14.6	-64.7	-38.6	17.8	63.1	20.3	10.4	-2.81	47
Income tax	0.07	-7.03	0.08	0.15	0.53	-31.1	4.75	5.45	-3.67	9.94
Net income to minority interests	2.22	0.86
Net income	-17	-8.39	-64.8	-38.7	17.2	94.2	15.5	4.95	0.86	37
EBITDA	-3.07	-1.9	-48.2	-26.1	31.1	78	28.1	23	12.3	60
EPS, basic	-0.26	-0.13	-0.90	-0.42	0.16	0.73	0.12	0.04	-0.01	0.16
EPS, diluted	-0.26	-0.13	-0.90	-0.42	0.15	0.70	0.12	0.04	-0.01	0.15
Shares, basic (weighted)	66.2	66.9	72.6	92.8	108	128	130	131	132	127
Shares, diluted (weighted)	66.2	66.9	72.6	92.8	111	134	132	133	132	130

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	1.86	2.36	21.4	60.4	84.4	114	102	104	136	93.7
Receivables		28.1	34.1	39.4	56.8	82.5	89.5	82	110	217
Inventory		14.3	13.3	22.9	27.8	25	24.8	28.3	26.2	29.6
Other current assets	0.4	4.4	2.33	2.95	4.94	4.97	5.09	10.5	13.7	18.4
Total current assets	1.44	49.7	71.1	126	174	227	223	225	286	362
Property, plant and equipment		42.1	39.6	47.2	55.8	79.2	102	116	89.1	104
Lease right-of-use assets					0	49.1	43.2	40.1	37.1	55.7
Goodwill		25.5	25.5	25.5	28.8	28.8	28.8	28.8	28.8	28.8
Intangible assets		29.8	26.1	20.8	30.6	25.7	20.8	15.9	12.5	9.15
Other non-current assets		0.74	0.58	0.88	0.67	1.54	1.52	5.99	5.01	9.2
Total assets	311	149	164	221	290	443	449	460	498	599
Accounts payable		19.1	19.2	28.4	23.4	29.3	32.3	30.7	28.9	31.9
Accrued liabilities	0.05	22.6	20.4	23.5	24	37.3	26.4	30.1	39.5	49.5
Total current liabilities	0.48	52	56.1	59.9	68.2	82.7	75	80.5	77.5	100
Long-term debt		14.8	12.6	49.6
Lease liabilities					0	46.9	20.9	25.1	25.2	22.5
Other non-current liabilities		1.53	5.93	6.65	7.97	1.56	1.12	1.21	0.89	1.19
Total liabilities	11.3	157	117	165	148	202	184	181	113	165
Total debt		52.1		49.6	70	74.1	71.3	66.6
Paid-in capital	5.23	50.1	177	227	297	302	311	320	303	303
Retained earnings	-0.23	-65.4	-130	-171	-155	-60.8	-45.3	-41	-40.1	-3.08
Shareholders' equity	-16	-15.3	39.9	52	142	241	266	279	263	300
Total equity	-16	-15.3	47	55.6	142	241	266	279	263	300
Total liabilities and equity	311	149	164	221	290	443	449	460	498	599
Shares outstanding		70.2	95.6	105	128	129	131	131	126	127

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-14.8	-7.53	-64.8	-38.7	17.2	94.2	15.5	4.95	0.86	37
Depreciation and amortization	5.7	3.59	3.31	3.78	4.44	5.78	5.85	10.4	13.6	15.3
Stock-based compensation	0.47	0.92	1.08	0.94	1.66	3.86	6.55	9	10.6	13.3
Deferred income tax		-7.3	0.19	0.11	0.11	-32	1.98	2.01	-10.7	9.5
Change in receivables	-6.56	-7.01	-7.11	-4.69	-17.6	-28.7	-8.77	5.54	-31.8	-116
Change in inventory	-5.37	-1.49	-1.52	-11.1	-6.7	-9.3	-9.41	-8.18	-6.2	-17.9
Change in payables	0.03	3.97	-0.06	4.7	-4.1	3.85	3.26	-0.11	-2.37	-0.53
Cash from operations	-4.87	-3.49	-60.6	-33.5	5.47	62	24.9	30.9	14.2	-10.3
Capital expenditures	-1.36	-2.43	-1.86	-5.98	-17.7	-31.2	-33.9	-24.4	-10	-14.2
Acquisitions		-11.8			-5.82
Cash from investing	-1.25	-14.9	-1.86	-6.23	-23.5	-31.2	-33.9	-24.4	-10	-14.2
Debt issued				50	10	73.2
Stock issued	304	0.22	92	50.3	64.7	2.2	2.07	0	1.25	0.16
Share buybacks							0	0	-25.5
Cash from financing	6.78	18.9	81.5	78.7	42.5	-1.04	-2.2	-5.51	27.6	-17.4
Net change in cash	0.66	0.5	19	39	24.4	29.7	-11.2	1.05	31.8	-41.8
Free cash flow	-6.23	-5.92	-62.5	-39.5	-12.2	30.8	-9.04	6.55	4.18	-24.5
Interest paid	3.97	6.08	5.42	8.15	9.61	5.79	2.65	5.44	4.97
Income taxes paid	0.03	0.1	0.01	0.05	0.06	0.61	1.2	3.05	6.97	5.35

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.41 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Operating margin	-7.8%	Operating income / revenue.
EBITDA margin	-4.4%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	-7.6%	Pre-tax income / revenue.
Net margin	-18.4%	Net income / revenue.
FCF margin	4.6%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	7.0%	Cash from operations / revenue.
Return on equity (ROE)	-56.8%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-20.7%	Net income / average total assets.
Return on invested capital (ROIC)	-27.7%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	12.5%	Research and development expense / revenue.
SG&A / revenue	65.4%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	3.1%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	2.4%	Capital expenditures / revenue.
D&A / revenue	3.5%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	17.0%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	7.8%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	10.8%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income CAGR, 3y	26.1%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	10.9%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	386.0%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	28.7%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	14.0%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	4,201.0%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 3y	33.6%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income CAGR, 5y	16.5%	Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS CAGR, 3y	7.7%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y	0.0%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	-172.6%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y	-685.7%	Free cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y	14.2%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	4.1%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	16.2%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	20.3%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	10.0%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	15.6%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-1.1%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-0.5%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	3.2%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	3.52x	Current assets / current liabilities.
Quick ratio	2.58x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.81x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	29.1%	Total liabilities / total assets.
Working capital	$143.3M	Current assets - current liabilities.
Goodwill and intangibles / assets	7.8%	(Goodwill + intangible assets) / total assets.
Tangible book value	$116.5M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	1.13x	Revenue / average total assets.
Fixed asset turnover	4.51x	Revenue / average property, plant and equipment.
Receivables turnover	4.53x	Revenue / average receivables.
Days sales outstanding	81 days	365 x average receivables / revenue.
Capex / operating cash flow	34.8%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$0.65	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$3.56	Revenue / diluted weighted shares.
FCF per share	$0.16	Free cash flow / diluted weighted shares.
Operating cash flow per share	$0.25	Cash from operations / diluted weighted shares.
Book value per share	$1.15	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$0.91	Tangible book value / shares outstanding.
Cash per share	$0.36	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$181.4M	Share price x shares outstanding.
Enterprise value	$135.3M	Market cap + total debt - cash - short-term investments.
P/S	0.40x	Market cap / revenue.
P/B	1.22x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	1.56x	Market cap / tangible book value, when positive.
P/FCF	8.71x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	5.67x	Market cap / cash from operations, when positive.
EV/Sales	0.30x	Enterprise value / revenue.
EV/FCF	6.49x	Enterprise value / free cash flow, when both are positive.
FCF yield	11.5%	Free cash flow / market cap.
Earnings yield	-46.4%	Net income / market cap (the inverse of P/E).

What was Organogenesis Holdings Inc.'s revenue in fiscal 2025?

Organogenesis Holdings Inc. reported revenue of $564.2M for fiscal 2025, 17% higher than the year before.

Was Organogenesis Holdings Inc. profitable in fiscal 2025?

Yes. Net income was $37.0M, a net margin of 6.6%.

How much free cash flow did Organogenesis Holdings Inc. generate in fiscal 2025?

Cash from operations of $10.3M minus capital expenditures of $14.2M left free cash flow of -$24.5M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Organogenesis Holdings Inc.